Enavate Sciences’s Braveheart Bio BRVE Stock Holding History
Bought
Maintained
Sold
Other funds holding BRVE
Enavate Sciences's BRVE Position: Q3 2026 in Review
Enavate Sciences opened a new position in Braveheart Bio (BRVE) in Q3 2026: 3,674,656 shares worth $74.2M. The stake represents 26.53% of the portfolio and ranks #3 among its holdings.
64 funds tracked by Wall St. Rank hold BRVE as of Q3 2026.
- Enavate Sciences held 3,674,656 shares of Braveheart Bio worth $74.2M as of Q3 2026.
- Braveheart Bio was a new Enavate Sciences position in Q3 2026.
- Braveheart Bio made up 26.53% of Enavate Sciences's portfolio in Q3 2026, its #3 holding.
- 64 funds tracked by Wall St. Rank held Braveheart Bio as of Q3 2026.
Based on Enavate Sciences's 13F filing for Q3 2026, filed 16 Nov 2026.